Welcome to our dedicated page for Attovia Therapeutics SEC filings (Ticker: ATTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Attovia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Attovia Therapeutics's regulatory disclosures and financial reporting.
Alamar HoldCo, LLC reported its initial beneficial ownership in Attovia Therapeutics, Inc. as a more than 10% holder on Form 3. The entity holds 3,229,278 shares of Common Stock directly. The remarks state that, in connection with the closing of Attovia’s initial public offering, Alamar HoldCo will cease to be a 10% holder.
Attovia Therapeutics, Inc. director Colin Walsh reported initial indirect holdings of the company’s preferred stock. The filing lists Series B Preferred Stock convertible into 1,957,140 shares of common stock and Series C Preferred Stock convertible into 478,501 shares of common stock, all held through Goldman Sachs–affiliated investment vehicles. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. is conducting an initial public offering of 17,000,000 shares of common stock at $17.00 per share, for a gross offering of $289,000,000. Underwriters have a 30-day option to purchase up to 2,550,000 additional shares to cover over-allotments. Net proceeds are estimated at $265.1 million (or $305.4 million with full exercise), after underwriting discounts and estimated expenses.
The company is a clinical-stage biopharmaceutical developer of next‑generation biologics for immune‑mediated diseases, built on its proprietary ATTOBODY platform. Lead candidate ATTO-1310 is in a Phase 1 trial for chronic pruritic diseases; ATTO-2306 (bispecific IL‑13/IL‑31) and ATTO-1091 (trispecific TL1A/IL‑23/integrin α4β7) are in IND‑enabling studies with planned Phase 1 trials in the first half of 2027.
As of March 31, 2026, Attovia held $132.6 million in cash, cash equivalents and marketable securities and reported an accumulated deficit of $129.7 million, reflecting net losses of $39.8 million in 2024 and $60.6 million in 2025. The company qualifies as an emerging growth company and smaller reporting company and expects the IPO proceeds, together with existing cash, to fund operations into 2029.
Attovia Therapeutics, Inc. lists initial equity holdings for Chief Scientific Officer Petter Veiby. He directly holds 104,951 shares of Common Stock. He also holds four stock option awards over Common Stock: 5,382 shares at an exercise price of $2.8799 expiring March 5, 2034; 107,642 shares at $3.5302 expiring May 8, 2034; 89,343 shares at $4.9237 expiring May 17, 2035; and 18,837 shares at $1.5793 expiring August 16, 2033. Each option vests over four years, with 25% vesting on specified initial dates in 2024–2026 and the remaining 75% vesting in equal monthly installments over three years, subject to continued service.
Attovia Therapeutics, Inc. director Royston Aaron filed an initial ownership report on Form 3. The filing lists his status as a director but does not report any equity transactions or current holdings, and no Rule 10b5-1 trading plan is indicated.
Attovia Therapeutics, Inc. reported the initial equity holdings of Chief Business Officer Zaneta Odrowaz. She directly holds 103,269 shares of common stock, including 17,156 unvested shares that continue to vest monthly and are scheduled to be fully vested on April 27, 2027, subject to continued service. She also holds stock options to purchase common stock, including options over 15,137 shares at $1.5793 per share expiring on August 16, 2033, 5,382 shares at $2.8799 expiring on March 5, 2034, 102,260 shares at $3.5302 expiring on May 8, 2034, and 85,037 shares at $4.9237 expiring on May 17, 2035. Each option vests over four years, with 25% vested on specified initial vesting dates and the remaining shares vesting in equal monthly installments over three years, contingent on continued service.
Attovia Therapeutics, Inc. reported the initial equity holdings of Chief Medical Officer Hubert Chen. As of August 4, 2026, he directly holds 2,960 shares of Common Stock and several stock options. These include options over 115,446 and 96,878 shares of Common Stock at an exercise price of $3.5302 per share expiring on May 8, 2034, and an option over 80,731 shares at an exercise price of $4.9237 per share expiring on May 17, 2035. Footnotes state that each option vests over four years: 25% of the underlying shares vested on specified dates in 2025 or 2026, with the remaining 1/48 of the total shares vesting in equal monthly installments over three years, subject to Dr. Chen’s continued service.